Evolution of the Average Target: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Average Target - Genmab A/S

Evolution of the Target Price: Genmab A/S

Data source: Genmab A/S(GMAB)
Evolution of the Target Price - Genmab A/S

Changes in Analyst Recommendations: Genmab A/S

Data source: Genmab A/S(GMAB)
c87b142c19701770bf7746d.lguTviVZI8jrOMsjpYclPQM2b-eZGmnTtvP4Js6_aUc.zlnWzG4IaJCsSYoX1dYWdXd8MKXcSAGMz4vNQZ3aAQvvSfaTSTcOkplbjg~0411ad8569b3079f1866a90e7079b31c
10:13pm Deutsche Bank raises price target for Genmab to DKK 4,000 (3,500), reiterates buy - BN FW
09:40pm AlphaValue/Baader Europe Downgrades Genmab to Sell MT
09:34pm Not All AI Billions Are Equal Zonebourse
05:46pm Goldman Sachs raises its price target for Genmab to 4,450 Danish kroner (2,400), reiterates buy FW
04:25pm Genmab: Positive developments priced in; time to take profits Alphavalue
03:48pm SEB raises price target for Genmab to DKK 4,600 (3,175), reiterates buy FW
03:47pm DNB Carnegie downgrades Genmab to hold (buy), target price DKK 4,100 (3,100) FW
03:06pm Jyske Bank cuts Genmab to sell (hold), price target DKK 3,725 - BN FW
02:29pm Nordea raises price target for Genmab to 4,500 Danish kroner (3,200), reiterates Buy FW
01:44pm Sydbank lowers Genmab to hold (buy) - BN FW
12:38pm TD Cowen raises price target for Genmab to DKK 4,526 (3,435), reiterates buy - LSEG FW
12:02pm Barclays raises price target for Genmab to 4,500 Danish kroner (3,400), reiterates overweight FW
10-28 AlphaValue/Baader Europe Downgrades Genmab to Reduce MT
10-26 Deutsche Bank raises price target for Genmab to 3,500 Danish kroner (3,000), reiterates buy FW
10-26 Jefferies raises target price for Genmab, boosts view on oncology portfolio FW
10-26 Genmab surges 13% on promising cancer data FW
10-26 BNP Paribas raises price target for Genmab to DKK3,300 (2,850), reiterates outperform - BN FW
10-26 Genmab boosted by promising advances, GTT penalized by disappointing results Zonebourse
10-26 Barclays raises price target for Genmab to 3,400 Danish kroner (3,100), reiterates overweight - BN FW
10-26 Jefferies raises price target for Genmab to 3,200 Danish kroner (2,900), reiterates buy FW
10-26 DNB Carnegie raises target price for Genmab to DKK 3,100 (2,850), reiterates buy FW
10-26 Nordea raises its price target for Genmab to 3,200 Danish kroner (2,811), reiterates buy FW
10-26 JP Morgan upgrades Genmab to overweight (neutral), target price DKK 3,500 - BN FW
10-26 SEB raises its price target for Genmab to DKK 3,175 (3,000), reiterates Buy FW
10-19 Nordea raises its price target for Genmab to DKK 2,811 (2,083), reiterates buy FW

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+41.72%
+26.36%
+10.61%
+10.61%
+16.9%
+37.16%
+42.61%
-17.48%
+30.19%
Average +22.07%
Weighted average by Cap. +22.71%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
3,868.00DKK
Average target price
3,191.92DKK
Spread / Average Target
-17.48%
High Price Target
3,500.00DKK
Spread / Highest target
-9.51%
Low Price Target
2,400.00DKK
Spread / Lowest Target
-37.95%

Analyst Consensus Detail

Analyst consensus - Genmab A/S

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Genmab A/S
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Genmab A/S